ADARx Pharmaceuticals Announces Positive Interim Phase 1 Clinical Data for its Novel siRNA Targeting Complement Factor B (CFB)

Single subcutaneous dose of ADX-038 achieved near-complete alternative pathway suppression for 6 months, supporting potent and selective CFB ...
ahajournals.org

Association Between Alternative Complement Pathway and Carotid Plaque and the Underlying Gut Microbial and Inflammatory Biomarkers: A Cohort Study

Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Department of Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China (H.C ...
C&EN

Complement C1q-Targeted Microglial Membrane Camouflaged Nanolipid Carriers for Synaptic Protection in Alzheimer’s Disease: A Bioinspired Alectinib Delivery Strategy

College of Life and Health Sciences, Northeastern University, Shenyang, P. R. China, 110819 College of Pharmacy, Shenzhen Technology University, Shenzhen, P. R. China ...
BioSpace

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906)

Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease portfolio Omeros is eligible to receive 340 million US dollars in ...
MedCity News

Novo Nordisk Gets New Complement System Approach to Rare Diseases With Deal for Omeros Drug

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...